title: Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review.
abstract: Respiratory syncytial virus (RSV) infection is an important cause of respiratory mortality in immunosuppressed patients, including bone marrow transplant (BMT) recipients. The presence of lower respiratory tract infection and infection in the pre-engraftment phase of BMT is believed to confer a poor prognosis. Three patients who underwent allogeneic BMT at our institution developed RSV pneumonia over 1 year post BMT, with the underlying disease in remission. All three were hypoxic with extensive pulmonary disease at presentation. Treatment consisted of aerosolized ribavirin and intravenous immune globulin with successful clearing of viral shedding and excellent clinical outcomes. RSV infection is probably less severe in the late post-BMT period, but needs to be considered early in the differential diagnosis of pulmonary infiltrates in this patient population.
authors: Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors: N I
authors: NI
authors: Khushalani
authors: F G
authors: FG
authors: Bakri
authors: D
authors: D
authors: Wentling
authors: K
authors: K
authors: Brown
authors: A
authors: A
authors: Mohr
authors: B
authors: B
authors: Anderson
authors: C
authors: C
authors: Keesler
authors: D
authors: D
authors: Ball
authors: Z P
authors: ZP
authors: Bernstein
authors: S H
authors: SH
authors: Bernstein
authors: M S
authors: MS
authors: Czuczman
authors: B H
authors: BH
authors: Segal
authors: P L
authors: PL
authors: McCarthy
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D008297:Male; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000209:etiology*; D012254:Ribavirin / Q000008:administration & dosage; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D016756:Immunoglobulins, Intravenous; D012254:Ribavirin